Development of betabodies: The next generation of phosphatidylserine targeting agents
Journal of Biological Chemistry · 2024-09 · 300 (9) · 107681
DOI: 10.1016/j.jbc.2024.107681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024-09. Verfasst von Natalie Z Phinney und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA; Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Ce…. Hauptthemen laut MEDLINE: Phosphatidylserines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCRR NIH HHS, NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
Externalized phosphatidylserine (PS) is a phospholipid and a selective marker of the tumor microenvironment (TME). It is exposed on the outer leaflet of the plasma membrane of tumor-associated endothelial cells, apoptotic tumor cells, and some viable tumor cells, where it functions in part to suppress immune responses by binding to PS receptors expressed on tumor-infiltrating myeloid cells. PS has been targeted with antibodies, such as bavituximab, that bind the phospholipid via a cofactor, β2-glycoprotein 1 (β2GP1); these antibodies showed excellent specificity for tumor vasculature and induce an immune stimulatory environment. We have advanced this concept by developing the next generation of PS targeting agent, a fusion protein (betabody) constructed by linking PS-binding domain V of β2GP1 to the Fc of an IgG2a. Betabodies bind to externalized PS with high affinity (∼1 nM), without the requirement of a co-factor and localize robustly to the TME. We demonstrate that betabodies are a direct PS-targeting agent that has the potential to be used as anti-tumor therapy, drug delivery vehicles, and tools for imaging the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA; Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas, USA; Cancer Biology Graduate Program, UT Southwes…
- Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas, USA; Department of Pharmacology, UT Southwestern Medical Center, Dallas, Texas, USA.
- Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA; Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas, USA.
Förderung
- NCRR NIH HHS
- NIDDK NIH HHS
- NIH HHS
- NCI NIH HHS
- NHGRI NIH HHS
- University of California, Davis
- National Institutes of Health
Zitieren
APA
Phinney, N. Z., Huang, X., Toombs, J. E., & Brekken, R. A. (2024). Development of betabodies: The next generation of phosphatidylserine targeting agents. Journal of Biological Chemistry, 300(9), 107681. https://doi.org/10.1016/j.jbc.2024.107681
Vancouver
Phinney NZ, Huang X, Toombs JE, Brekken RA. Development of betabodies: The next generation of phosphatidylserine targeting agents. Journal of Biological Chemistry. 2024;300(9):107681. doi:10.1016/j.jbc.2024.107681
BibTeX
@article{Phinney2024,
author = {Phinney, Natalie Z and Huang, Xianming and Toombs, Jason E and Brekken, Rolf A},
title = {Development of betabodies: The next generation of phosphatidylserine targeting agents},
journal = {Journal of Biological Chemistry},
year = {2024},
volume = {300},
number = {9},
pages = {107681},
doi = {10.1016/j.jbc.2024.107681}
}
EUVIMED